Clinical trials: Psychological Disorders
- Condition Psychological Disorders
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Bipolar Disorder
Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898)
This study will investigate the safety and tolerability of a flexible dosing regimen of asenapine for the long-term treatment of manic or mixed episodes associated with bipolar disorder I in children and adolescents who completed…
- Trial name
- ADDRESS-98 (NCT01349907)
- Testing
- Asenapine, Rescue medication
- Volunteers
- 322 people
- Sponsor
- Organon and Co
Alzheimer Disease
Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease
Evaluate safety, tolerability, and pharmacokinetics of single doses of the investigational AAB-001 Vaccine in Japanese patients with Alzheimer's disease.
- Trial name
- NCT00397891
- Testing
- bapineuzumab
- Where
- 4 sites in Japan
- Volunteers
- 80 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia
The purpose of this study is to explore changes in efficacy, cognitive functioning, and safety of flexibly-dosed Brexpiprazole monotherapy in subjects with acute schizophrenia
- Trial name
- NCT02054702
- Testing
- Brexpiprazole, Aripiprazole
- Volunteers
- 97 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
- Trial name
- ARRIVE- EU (NCT01509053)
- Testing
- Aripiprazole (Abilify®) IM Depot Injection, Oral aripiprazole
- Where
- 10 sites in Belgium, Bulgaria and 1 more
- Volunteers
- 30 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Substance Use Disorders
Woebot for Substance Use Disorders
Phase 1 of this study aims to develop a digitally-delivered substance use disorder program through the Woebot app-based platform (W-SUDs) and evaluate the effectiveness of, patient satisfaction with and the acceptability of…
- Trial name
- NCT04096001
- Testing
- Woebot-SUDs (W-SUDs)
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Woebot Health
Alzheimer's Disease
A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease
The study is designed to investigate the effects of rilapladib on biomarkers related to the Alzheimer's disease, and cognitive function.
- Trial name
- NCT01428453
- Testing
- 250mg rilapladib
- Where
- 30 sites in Bulgaria, Canada and 5 more
- Volunteers
- 124 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
The purpose of this study is to evaluate the changes in the cognitive, functional, behavioral and global domains based on the different applicable psychometric batteries and scales.
- Trial name
- AMBAR (NCT01561053)
- Testing
- Albumin 5%, Albumin 20%, Immunoglobulin
- Where
- 40 sites in United States, Spain
- Volunteers
- 347 people
- Sponsor
- Instituto Grifols, S.A.
Schizophrenia
Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia
A Multicentre, Open-label, Prospective Long-term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR® (Quetiapine Fumarate Extended-Release Tablets) in Subjects with Schizophrenia.
- Trial name
- SPECTRUM (NCT00640601)
- Testing
- Quetiapine Fumarate Extended- Release
- Where
- 36 sites in Australia, Canada and 2 more
- Volunteers
- 331 people
- Sponsor
- AstraZeneca
Alzheimer's Disease
The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease
This study attempts to differentiate the clinical responses of Choline Acetyltransferase and Apolipoprotein Epsilon gene polymorphism to donepezil in Alzheimer's Disease patients.
- Trial name
- NCT00381381
- Testing
- Donepezil
- Where
- 15 sites in South Korea
- Volunteers
- 199 people
- Sponsor
- Eisai Korea Inc.
Parkinson Disease, Cognitive Dysfunction
A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Parkinson's disease mild cognitive impairment (PD-MCI).
- Trial name
- NCT05318937
- Testing
- SAGE-718
- Where
- 38 sites in United States
- Volunteers
- 86 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Schizophrenia
A Study of Olanzapine in Patients With Schizophrenia
The primary objectives of the study is to confirm if the efficacy of intramuscular injection (IM) olanzapine 10 milligrams (mg) in patients with an exacerbation of schizophrenia with acute psychotic agitation is greater than…
- Trial name
- NCT00970281
- Testing
- Rapid-Acting Intramuscular Olanzapine
- Where
- 11 sites in Japan
- Volunteers
- 91 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Safety and Tolerability Study of Drug to Treat Schizophrenia
The purpose of this study is to evaluate the long-term safety of SM-13496 in patients with schizophrenia.
- Trial name
- NCT00044005
- Testing
- Lurasidone 20 mg, Lurasidone 40 mg, Lurasidone 80mg
- Where
- 26 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sumitomo Pharma America, Inc.
Agitation, Dementia
An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia
A randomized, double-blind, placebo-controlled parallel group 3-arm study assessing efficacy, safety, and tolerability of two doses BXCL501 in male and female geriatric residents (65 years and older) with acute agitation…
- Trial name
- NCT05276830
- Testing
- BXCL501
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- BioXcel Therapeutics Inc
Depressive Disorder, Major
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOX®) compared with placebo as treatment for major depressive disorder (MDD) in adult females.
- Trial name
- NCT02116361
- Testing
- onabotulinumtoxinA, Normal Saline
- Where
- 35 sites in United States
- Volunteers
- 258 people
- Sponsor
- Allergan
Dementia, Vascular, Alzheimer Disease
LEAD IT! An App to Enable Persons With Early Stage Dementia to Lead Group Activities for Their Peers
The proposed Phase 2 project will involve the further development and evaluation of LEAD IT!, which is a tablet-based app designed to enable persons with dementia to lead activities for their peers (i.e., other persons with…
- Conditions
- Dementia, Vascular, Alzheimer Disease, Dementia, Mixed
- Trial name
- NCT05516342
- Testing
- LEAD IT! Programming
- Where
- United States
- Volunteers
- 182 people
- Sponsor
- Hopeful Aging
Schizophrenia, Paranoid, Schizophrenia, Disorganized
Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)
This study is designed to evaluate whether asenapine, which is approved by the United States Food and Drug Administration (US FDA) for acute treatment of schizophrenia in adults, is also effective in adolescents with…
- Conditions
- Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated
- Trial name
- NCT01190254
- Testing
- asenapine 2.5 mg, asenapine 5.0 mg
- Volunteers
- 306 people
- Sponsor
- Organon and Co
Major Depressive Disorder, Treatment Resistant Depression
Open-Label Safety Study of AXS-05 in Subjects With Depression
An open-label, long-term, safety study of AXS-05 in patients with major depressive disorder (MDD), including treatment resistant depression.
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, Depression
- Trial name
- NCT04039022
- Testing
- AXS-05 (dextromethorphan and bupropion) oral tablets
- Where
- 51 sites in United States
- Volunteers
- 876 people
- Sponsor
- Axsome Therapeutics, Inc.
Attention Deficit Hyperactivity Disorder
A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder
The primary purpose of the study is to assess long-term safety and tolerability of Edivoxetine in pediatric participants with attention deficit hyperactive disorder (ADHD).
- Trial name
- NCT00965419
- Testing
- Edivoxetine
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 267 people
- Sponsor
- Eli Lilly and Company
Tourette's Disorder
Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
The goal of the current study is to determine efficacy and safety of once-weekly aripiprazole in reducing Total Tic Severity (TTS) score in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01418339
- Testing
- Aripiprazole
- Where
- 39 sites in United States, Canada and 4 more
- Volunteers
- 135 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Parkinson's Disease Psychosis
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
- Trial name
- NCT00477672
- Testing
- Pimavanserin tartrate (ACP-103)
- Where
- 78 sites in United States, Bulgaria and 5 more
- Volunteers
- 298 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.